天津医药

天津医药 ›› 2021, Vol. 49 ›› Issue (8): 842-846.doi: 10.11958/20210292

• 临床研究 • 上一篇    下一篇

RNA结合蛋白Musashi2与宫颈鳞状细胞癌关系的研究

甄娟 1，刘玉东 2，宋春红 1△，吴莎 1，毕学杰 1   

  1. 1石家庄市第四医院/河北医科大学附属妇产医院病理科（邮编050011）；2河北省人民医院耳鼻咽喉科
  • 收稿日期:2021-02-01 修回日期:2021-04-12 出版日期:2021-08-15 发布日期:2021-08-19
  • 通讯作者: 宋春红 E-mail:trirainbow@126.com
  • 作者简介:甄娟（1983），女，硕士，副主任医师，主要从事妇科肿瘤研究。E-mail：76147125@qq.com
  • 基金资助:
    河北省医学科学研究重点课题计划（20181070）

The relationship between the expression of RNA-binding protein Musashi2 and cervical squamous-cell carcinoma

ZHEN Juan1, LIU Yu-dong2, SONG Chun-hong1△, WU Sha1, BI Xue-jie1   

  1. 1 Department of Pathology, Shijiazhuang Fourth Hospital (Obstetrics and Gynecology Hospital Affiliated to Hebei Medical University), Shijiazhuang 050011, China; 2 Department of Otorhinolaryngology, Hebei General Hospital △Corresponding Author E-mail: trirainbow@126.com
  • Received:2021-02-01 Revised:2021-04-12 Published:2021-08-15 Online:2021-08-19

PDF (PC)

3164

摘要： 目的 探讨宫颈鳞状细胞癌组织中RNA结合蛋白Musashi2（MSI2）的表达与临床病理因素的关系及其临 床意义。方法 采用免疫组化（SP）法检测40例正常宫颈组织、60例高级别鳞状上皮内病变组织和126例宫颈鳞状 细胞癌组织中MSI2的蛋白表达水平，分析其表达与临床病理因素及患者预后的关系。Western blot法检测30例宫颈 鳞状细胞癌和30例癌旁正常宫颈组织中MSI2的相对表达量。结合患者随访资料，分析影响宫颈鳞状细胞癌患者预 后的危险因素。结果 免疫组化结果表明，正常宫颈组织（7.50%）、高级别鳞状上皮内病变组织（28.33%）和宫颈鳞 状细胞癌组织（61.90%）中MSI2的阳性表达率逐渐升高（P＜0.05），FIGOⅢ+Ⅳ期、有淋巴结转移、HPV16感染及Ki67 高表达者MSI2阳性率更高（均P＜0.05）。Western blot结果显示，宫颈鳞状细胞癌组织中MSI2的相对表达量高于癌 旁正常宫颈组织（0.80±0.09 vs. 0.24±0.06，P＜0.05）。生存分析显示，MSI2阳性表达的宫颈鳞状细胞癌患者的生存时 间明显短于阴性表达者（Log-rank χ2=6.413，P＜0.05），FIGOⅠ+Ⅱ分期、无淋巴结转移者生存时间较长（均P＜0.05）。 Cox多因素回归分析显示，MSI2阳性表达、FIGOⅢ+Ⅳ期和淋巴结转移均是宫颈鳞状细胞癌患者生存的危险因素（均 P＜0.05）。结论 MSI2在宫颈鳞状细胞癌中高表达，并且与肿瘤进展转移及患者预后关系密切。

关键词: 癌, 鳞状细胞, 宫颈肿瘤, 预后, 存活率分析, RNA结合蛋白质类, RNA结合蛋白Musashi2

Abstract: Objective To investigate the relationship between expression of RNA-binding protein Musashi2 (MSI2) and clinical pathology significance of cervical squamous-cell carcinoma (CSCC). Methods Immunohistochemical staining was applied to detect the expression levels of MSI2 in 40 cases of normal uterine cervix, 60 cases of high-grade squamous intraepithelial lesion (HSIL) and 126 cases of CSCC. The correlation between MSI2 expression, clinicopathological factors and prognosis was analyzed. Western blot assay was used to detect the relative expression of MSI2 in 30 cases of CSCC and 30 cases of paracancerous cervical tissues. In combination with the follow-up data, the risk factors affecting the prognosis in patients with cervical squamous cell carcinoma were evaluated. Results The immunohistochemistry results showed that ere was an increasing tendency in positive rates of MSI2 expression in uterine cervix (7.50%), high-level squamous intraepithelial lesions (HSIL, 28.33%) and cervical squamous cell carcinoma (CSCC, 61.90%, P＜0.05). The positive rates of MSI2 were higher in CSCC with FIGOⅢ+Ⅳstage, lymph node metastasis, HPV16 infection and high expression of Ki67 (P＜ 0.05). The relative expression of MSI2 was significantly higher in cervical squamous cell carcinoma than that in adjacent cervical tissues（0.80±0.09 vs. 0.24±0.06, P＜0.05). Univariate survival analysis showed that the overall survival time (OS) was significantly lower in patients with MSI2 positive expression than that of patients with negative expression (Log-rank χ2= 6.413，P＜0.05). The patients with MSI2 negative expression, FIGO Ⅰ + Ⅱ stage and no lymph node metastasis showed higher quality of life (P＜0.05). Cox multivariate regression analysis showed that MSI2 positive expression, FIGOⅢ+Ⅳ stage and lymph node metastasis were risk factors for CSCC (P＜0.05). Conclusion High expression of MSI2 in cervical squamous-cell carcinoma is associated with tumor progression, metastasis and patient prognosis.

Key words: carcinoma, squamous cell, uterine cervical neoplasms, prognosis, survival analysis, RNA-binding proteins, RNA binding protein Musashi2

中图分类号: